Vogel C L
South Florida Comprehensive Cancer Centers, Miami, USA.
Semin Oncol. 1995 Apr;22(2 Suppl 5):61-5.
Trials establishing the safety and efficacy of single-agent vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France) as first- and second-line chemotherapy for metastatic breast cancer led to testing of the combination of vinorelbine and mitoxantrone. Three phase II clinical trials in Europe and South America, and one phase I trial in the United States have studied the effects of this combination on advanced breast cancer. In the two phase II trials that used vinorelbine and mitoxantrone only, response rates were 56% for patients who received the combination as first-line therapy and 36% for those who were anthracycline resistant. A third phase II trial looked at the effects of a combination of mitoxantrone and vinorelbine plus ifosfamide with mesna in patients who had failed at least two prior chemotherapy regimens; a 41% response rate was noted. In the phase I trial, the combination of vinorelbine and mitoxantrone with prophylactic granulocyte colony-stimulating factors was explored. Further trials are needed to study the combination of vinorelbine and mitoxantrone.
多项试验证实了单药长春瑞滨（诺维本；百时美施贵宝公司，北卡罗来纳州三角研究园；法国巴黎皮尔法伯制药公司）作为转移性乳腺癌一线和二线化疗药物的安全性和有效性，随后对长春瑞滨与米托蒽醌联合用药进行了试验。欧洲和南美洲的三项II期临床试验以及美国的一项I期试验研究了该联合用药方案对晚期乳腺癌的疗效。在仅使用长春瑞滨和米托蒽醌的两项II期试验中，接受该联合用药方案作为一线治疗的患者缓解率为56%，对蒽环类药物耐药的患者缓解率为36%。第三项II期试验观察了米托蒽醌、长春瑞滨联合异环磷酰胺加美司钠在至少两种先前化疗方案治疗失败的患者中的疗效；观察到缓解率为41%。在I期试验中，探索了长春瑞滨、米托蒽醌联合预防性粒细胞集落刺激因子的用药方案。还需要进一步的试验来研究长春瑞滨与米托蒽醌的联合用药。
